Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 关于艾沙力?/ 喜沙立?（乌司奴单抗注射液）获得药品注册证书的公告
Regulatory Filings Classification · 89% confidence The document is a corporate announcement by 百奥泰生物制药股份有限公司 regarding receipt of drug registration certificates from the NMPA for its biologic products. It contains no financial statements, management or board changes, or proxy materials. It is a general regulatory announcement of product approval. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-21 Chinese
百奥泰 关于Immgolis?/ Immgolis Intri?（戈利木单抗注射液）获美国FDA上市批准的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement (公告) informing investors that the FDA has approved the company’s drug Immgolis/Immgolis Intri™. It contains no financial statements or management changes, nor is it a formal earnings or annual report. It is a routine regulatory disclosure of material news. Under our taxonomy, this best fits as a general regulatory announcement (RNS), rather than a financial report or specific form filing.
2026-05-18 Chinese
百奥泰 自愿披露关于注射用BAT8013获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 89% confidence The document is a voluntary corporate announcement disclosing the receipt of a clinical trial approval notice from China’s National Medical Products Administration. It contains no financial statements, no management changes, no share transactions, no dividend or capital structure information, and no reference to an earnings or regulatory report attachment. It is a compliance announcement of an operational event (regulatory approval) and does not fit any specific financial report categories. Therefore it falls under the generic Regulatory Filings category (RNS).
2026-05-12 Chinese
百奥泰2025年度独立董事述职报告（HENRYWEI魏亨利）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by Henry Wei, an independent director of the company. It details the director's duties, attendance at board and shareholder meetings, audit committee involvement, communication with auditors, oversight of financial reports, and evaluation of governance and compliance matters during the reporting period. The content focuses on the independent director's role, responsibilities, and observations rather than presenting full financial statements or comprehensive company financial performance. It is a specialized report related to board/management oversight and governance rather than a full annual report or audit report. Therefore, the document fits best under the category of Board/Management Information (MANG), which includes announcements or reports about changes or activities of the board or senior management, including independent directors' reports.
2026-04-27 Chinese
百奥泰 关于全资子公司申请贷款业务及公司为其提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by 百奥泰生物制药股份有限公司 regarding its wholly-owned subsidiary's loan application and the company's provision of guarantee for that loan. It includes detailed information about the loan amount, terms, collateral, internal decision-making processes, and board approvals. The document is structured as a public disclosure of a financing and guarantee arrangement rather than a financial report, earnings release, or management discussion. It does not contain financial statements or substantive financial data but focuses on the loan and guarantee update. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3563 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2026-04-27 Chinese
百奥泰2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' for the fiscal year 2025. It is issued by a certified public accounting firm (立信会计师事务所) and includes an audit opinion on the effectiveness of internal controls over financial reporting as of December 31, 2025. The content includes auditor responsibilities, management responsibilities, and an audit opinion, consistent with a standalone audit report on internal controls rather than a full annual report or interim report. The document length is 2818 characters, which is relatively short but contains substantive audit content, not merely an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR).
2026-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.